Mode
Text Size
Log in / Sign up

Multi-marker models show higher diagnostic performance than single analytes for identifying recurrent implantation failureMulti-marker models show promise for diagnosing recurrent implantation failure

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that multi-marker models show higher diagnostic potential for RIF than single analytes, but clinical use is not yet established.

This systematic review synthesized findings from 18 studies regarding the diagnostic and prognostic potential of fluid-based biomarkers (blood, uterine fluid, and menstrual fluid) in patients with recurrent implantation failure. The authors evaluated both single analytes and multi-marker models to determine their efficacy in identifying the condition.

Key findings indicate that multi-marker models achieved higher diagnostic performance than single analytes, reaching an AUC up to 0.94. In contrast, single analyte markers such as lymphocyte count showed lower performance with an AUC of 0.577. Regarding prognostic potential, plasma D-dimer demonstrated an AUC of approximately 0.81 for predicting pregnancy outcomes, while immune-cell profiling models reached an AUC of approximately 0.72. A four-protein panel in uterine fluid was noted as having promising diagnostic performance.

The authors highlighted significant limitations, including substantial methodological heterogeneity and a lack of eligible studies assessing menstrual fluid. Furthermore, they noted limited prognostic evidence for blood biomarkers. Due to these factors, the current evidence is insufficient to support routine clinical implementation at this time.

How this fits prior evidence

This systematic review addresses a gap in identifying diagnostic tools for recurrent implantation failure. While previous coverage identified that endometrial CD8+ T cells predict reproductive outcomes and that PRP infusion improves pregnancy rates but may increase preterm births, these findings focus on cellular markers and therapeutic interventions. The current evidence specifically highlights the superior diagnostic performance of multi-marker models over single analytes to identify the condition.

For many people trying to conceive, the heartbreak of repeated failed pregnancies is a heavy burden. This condition, known as recurrent implantation failure (RIF), can be incredibly difficult to diagnose because it involves complex biological factors. Researchers looked at 18 different studies to see if testing specific fluids—like blood or uterine fluid—could help doctors identify why these failures happen.

The data suggests that using a multi-marker model, which looks at several indicators at once, performs much better than looking at just one single marker. For example, while a single lymphocyte count showed low accuracy, combined models reached high diagnostic scores. Some specific tests, like a four-protein panel in uterine fluid or certain immune-cell profiling models, also showed promise for predicting pregnancy outcomes.

While these results are encouraging, it is important to take them with a grain of caution. The researchers noted that the studies were very different from one another and there isn't enough evidence yet to use these tests in everyday clinical practice. Currently, there is limited information on how blood markers predict outcomes, and no studies looked at menstrual fluid.

What this means for you:
Combining multiple biomarkers may be more accurate than single tests for diagnosing implantation failure.

Common questions

How do multi-marker models compare to single tests?

Multi-marker models showed higher diagnostic performance than single analytes. For example, while a single lymphocyte count had an AUC of 0.577, multi-marker models reached an AUC of up to 0.94. This suggests that looking at several markers together provides a clearer picture for diagnosis.

Can these tests help predict pregnancy outcomes?

Some tests show promise for predicting outcomes. Plasma D-dimer had an AUC of about 0.81, and immune-cell profiling models showed an AUC of about 0.72. However, the evidence for using blood biomarkers to predict outcomes is currently limited.

Can these tests be used in clinics right now?

Not yet. While some markers like the four-protein panel in uterine fluid show promise, there is currently insufficient evidence to use these tests for routine clinical care. You should speak with your doctor about the best diagnostic path for your specific situation.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
BackgroundRecurrent implantation failure (RIF) remains a significant challenge in reproductive medicine, with diagnostic approaches that are limited and widely debated. This systematic review evaluates whether fluid-based biomarkers from blood, uterine fluid, and menstrual fluid can provide more accessible and clinically informative alternatives.MethodsA systematic search of MEDLINE, Embase, Scopus, and Web of Science was conducted (2015–2025). Study quality was assessed using QUADAS-2 for diagnostic studies and PROBAST for prognostic studies. Due to substantial methodological heterogeneity, meta-analysis was not performed. Findings were synthesized narratively, and diagnostic performance was summarized using forest plots of reported AUC values without statistical pooling.ResultsFrom 3,105 records, 18 studies met the inclusion criteria. The evidence base was dominated by blood-based biomarkers (n = 17). Multi-marker models consistently demonstrated higher diagnostic performance than single analytes, with immune-cell profiling panels and cytokine–clinical parameter models achieving AUC values up to 0.94. In contrast, individual biomarkers generally showed lower performance (e.g., lymphocyte count, AUC = 0.577). Prognostic evidence for blood biomarkers was limited, although plasma D-dimer (AUC ≈ 0.81) and immune-cell profiling models (AUC ≈ 0.72) showed potential for predicting pregnancy outcomes. Only one study evaluated uterine fluid biomarkers, identifying a four-protein panel with promising diagnostic performance, while no eligible studies assessed menstrual fluid.ConclusionFluid-based biomarkers, particularly multi-marker models, may have diagnostic potential in RIF; however, current evidence remains insufficient to support routine clinical implementation. Future research should prioritize prospective validation of blood-based multi-marker models in standardized, euploidy-controlled cohorts, alongside greater investigation of biologically proximal uterine and menstrual biofluids.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251068643.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.